CALL US AT 800-952-0521
Search
Close this search box.

FDA Approves BELOTERO Balance®: Success of a Promising Partnership Between Anteis and Merz Aesthetics

Tuesday, November 22, 2011

GENEVA and PLAN-LES-OUATES, Switzerland, November 21, 2011 /PRNewswire/ —
BELOTERO Balance® has now been approved by the US Food and Drug Administration (FDA) for injection into the mid-to-deep dermis to correct moderate-to-severe facial wrinkles and folds such as nasolabial folds. BELOTERO Balance® is a hyaluronic acid-based cohesive gel dermal filler that delivers natural-looking results with little recovery time. “We are pleased to announce this FDA approval for BELOTERO Balance®. It represents a significant milestone for Anteis and Merz Aesthetics, Inc.”, stated Gilles Bos, Chief Executive Officer of Anteis and Dennis Condon, President and CEO of Merz Aesthetics, Inc.
Practitioners and patients will now have a breakthrough alternative in aesthetic medicine with BELOTERO Balance® “thanks to a successful partnership between Anteis, a Swiss leader in aesthetic dermatology, ophthalmology and orthopaedics, and Merz Aesthetics, a division of Merz Pharmaceuticals in Germany”, added Gilles Bos and Dennis Condon.
Since 2004, this partnership has encompassed the BELOTERO Balance® range in markets such as the United Kingdom, Germany, Italy, Russia, Austria and Switzerland. This medical device is currently approved for aesthetic use and distributed worldwide by Anteis under the brand name of Esthélis[TM]Basic.

https://www.facialesthetics.org/blog/fda_approves_belotero_balance%C3%A2_success_of_a_promising_partnership_between_anteis_and_merz_aesthetics

Blog Categories

Related Posts